InterPAD - DETAILS

Nutlin-3, 548472-68-0, 890090-75-2, (Rac)-Nutlin-3, nutlin 3, 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one, Nutlin, 4-[[4,5-Bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone, 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one, (+/-)-Nutlin3, CHEMBL211045, MFCD07784509, C30H30Cl2N4O4, (+)-Nutlin-3, MFCD14636430, Nutlin 3(Random Configuration), NSC-732664, Rac-Nutlin-3, Nutln 3A, 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one, (?)-Nutlin-3, the p53/MDM2 Agonist, SCHEMBL2458627, BDBM31197, CHEBI:93777, EX-A851, BDUHCSBCVGXTJM-UHFFFAOYSA-N, HMS3651G03, HMS3653F08, HMS3653J08, HMS3750A11, AMY39899, BCP02265, BCP05161, BCP29278, HY-10029A, MFCD11977784, NSC732664, s1061, AKOS005146527, CCG-264800, SB19406, SB19407, NCGC00165848-01, NCGC00165848-02, (+/-)-4-[4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one, 4-{[4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5- dihydro-1H-imidazol-1-yl]carbonyl}-2-piperazinone, AC-35939, AS-10121, DA-41729, SY283510, SY289992, DB-003450, DB-015048, CS-0007767, FT-0700329, FT-0713388, FT-0771774, FT-0773561, SW220144-1, H10266, A861337, J-514247, J-523776, BRD-A12230535-001-01-8, Q27165473, Z2159890360, (+-)-4-[4,5-dihydro-imidazole-1-carbonyl]piperazin-2-one, (-)-4-(4,5-bis-(4-Chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazole-1-carbonyl)piperazine-2-one, (??)-4-[4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one, 4-{[(4S,5R)-4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazol-1-yl]carbonyl}-2-piperazinone, RG7112;R7112;rel-4-((4R,5S)-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one

No.	Title	Href
1	The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway. Int J Biochem Cell Biol. 2019 Jan;106:8-20. doi: 10.1016/j.biocel.2018.10.008.	`Click`

No.

Title

Href

The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway. Int J Biochem Cell Biol. 2019 Jan;106:8-20. doi: 10.1016/j.biocel.2018.10.008.

Click

Name	Nutlin-3
PubChem CID	216345
Molecular Weight	581.5g/mol
Synonyms	Nutlin-3, 548472-68-0, 890090-75-2, (Rac)-Nutlin-3, nutlin 3, 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one, Nutlin, 4-[[4,5-Bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone, 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one, (+/-)-Nutlin3, CHEMBL211045, MFCD07784509, C30H30Cl2N4O4, (+)-Nutlin-3, MFCD14636430, Nutlin 3(Random Configuration), NSC-732664, Rac-Nutlin-3, Nutln 3A, 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one, (?)-Nutlin-3, the p53/MDM2 Agonist, SCHEMBL2458627, BDBM31197, CHEBI:93777, EX-A851, BDUHCSBCVGXTJM-UHFFFAOYSA-N, HMS3651G03, HMS3653F08, HMS3653J08, HMS3750A11, AMY39899, BCP02265, BCP05161, BCP29278, HY-10029A, MFCD11977784, NSC732664, s1061, AKOS005146527, CCG-264800, SB19406, SB19407, NCGC00165848-01, NCGC00165848-02, (+/-)-4-[4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one, 4-{[4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5- dihydro-1H-imidazol-1-yl]carbonyl}-2-piperazinone, AC-35939, AS-10121, DA-41729, SY283510, SY289992, DB-003450, DB-015048, CS-0007767, FT-0700329, FT-0713388, FT-0771774, FT-0773561, SW220144-1, H10266, A861337, J-514247, J-523776, BRD-A12230535-001-01-8, Q27165473, Z2159890360, (+-)-4-[4,5-dihydro-imidazole-1-carbonyl]piperazin-2-one, (-)-4-(4,5-bis-(4-Chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazole-1-carbonyl)piperazine-2-one, (??)-4-[4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one, 4-{[(4S,5R)-4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazol-1-yl]carbonyl}-2-piperazinone, RG7112;R7112;rel-4-((4R,5S)-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one
Drug Type	Small molecule
Formula	C₃₀H₃₀Cl₂N₄O₄
SMILES	CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl
InChI	1S/C30H30Cl2N4O4/c1-18(2)40-25-16-23(39-3)12-13-24(25)29-34-27(19-4-8-21(31)9-5-19)28(20-6-10-22(32)11-7-20)36(29)30(38)35-15-14-33-26(37)17-35/h4-13,16,18,27-28H,14-15,17H2,1-3H3,(H,33,37)
InChIKey	BDUHCSBCVGXTJM-UHFFFAOYSA-N
CAS Number	548472-68-0
ChEMBL ID	CHEMBL211045
ChEBI ID	CHEBI:93777
TTD ID	D01QKK
Drug Bank ID	DB17039
Toxicity	Organism	Test Type	Route(Dose)
Structure			Download 2D MOL 3D MOL

Pair Name	Tanshinone IIA, Nutlin-3
Partner Name	Tanshinone IIA
Disease Info	[ICD-11: 2A60.Z]	Acute myeloid leukemia		Investigative
Biological Phenomena	Induction-->Autophagy
Gene Regulation	Down-regulation	Expression	AKT1	hsa207
Gene Regulation	Down-regulation	Expression	MTOR	hsa2475
In Vitro Model	SUP-B15	Childhood B acute lymphoblastic leukemia with t	Homo sapiens (Human)	CVCL_0103
	NALM-6	Adult B acute lymphoblastic leukemia	Homo sapiens (Human)	CVCL_0092
	HL-60	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_0002
	MV4-11	Childhood acute monocytic leukemia	Homo sapiens (Human)	CVCL_0064
Result	The results of this study demonstrate that the Nutlin-3 plus Tanshinone IIA combination exerts synergistic anti-leukemia effects by regulating the p53 and AKT/mTOR pathways, although further investigation is warranted. Small-molecule MDM2 antagonists plus Tanshinone IIA may thus be a promising strategy for the treatment of acute leukemia.